Clinical Trials
79 trialsCD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
RenJi Hospital
Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI
Second Affiliated Hospital, School of Medicine, Zhejiang University
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
COPA-R-CHOP
University Hospital Muenster
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Zhejiang Cancer Hospital
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
BeBetter Med Inc
A Combination Study of CAR-T Therapy in r/r B-NHL
Ruijin Hospital
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Liaoning Cancer Hospital & Institute
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Decitabine and Anti-PD-1 in R/R DLBCL
Chinese PLA General Hospital
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
The First Affiliated Hospital of Soochow University
Relyage
Centre Hospitalier Universitaire, Amiens
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
The First Affiliated Hospital of Soochow University
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Huazhong University of Science and Technology
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Swedish Medical Center
The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.
First Affiliated Hospital of Wenzhou Medical University
ZR-CHOP in DLBCL With Specific Gene Abnormality
Fudan University
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
The First Affiliated Hospital with Nanjing Medical University
A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
Ruijin Hospital
Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL
Second Affiliated Hospital, School of Medicine, Zhejiang University
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
R2DLBCL80
Guangdong Provincial People's Hospital
Borma
Samsung Medical Center
Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma
Nanfang Hospital, Southern Medical University
Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma
ChineseAMS
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients
Ruijin Hospital
Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.
ChineseAMS
LEGEND
Royal Marsden NHS Foundation Trust
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL
Sun Yat-sen University
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Sheba Medical Center
Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.
The First Affiliated Hospital with Nanjing Medical University
EPIC
Seoul National University Hospital
DLBCL
First Affiliated Hospital of Zhejiang University
Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma
Asan Medical Center
IVAM
Asan Medical Center
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Fudan University
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
Ruijin Hospital
Chidamide Plus R-CHOP in Elderly DLBCL
Ruijin Hospital
RICE-ibrutinib in Relapsed DLBCL
Singapore General Hospital
STORM
University Hospital Heidelberg
a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
Southwest Hospital, China